Elotuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Elotuzumab?
Monoclonal antibody
Type Whole antibody
Source Humanized
Target SLAMF7 (CD319)
Clinical data
  • Experimental
Identifiers
915296-00-3 N
None
UNII 1351PE5UGS YesY
Chemical data
Formula C6476H9982N1714O2016S42
145.5 kDa
 N (what is this?)  (verify)

Elotuzumab (also known as HuLuc63) is a humanized monoclonal antibody which is under phase III clinical investigation in relapsed multiple myeloma.[1] In May 2014, it was granted "Breakthrough Therapy" designation by the FDA. [2]

References[edit]